Detail akcie Medicus Pharma Rg online

Business Summary: Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Medicus Pharma Ltd revenues was not reported. Net loss applicable to common stockholders increased from $7.6M to $32.2M. Higher net loss reflects Life sciences and bio-technology segment loss increase from $4M to $26.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.90 to -$1.97.